Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy in Treating Young Patients With Langerhans Cell Histiocytosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histopathologically confirmed diagnosis of Langerhans cell histiocytosis according to the criteria defined by the Histiocyte Society~  * Demonstration of CD1a antigenic determinants on the surface of lesional cells (by immunocytology or immunohistology) or Birbeck granules in lesional cells by electron microscopy~* Considered at risk or low risk according to the following criteria:~  * Multi-system at risk disease, defined as involvement of one or more risk organs (i.e., hematopoietic system, liver, spleen, or lungs)~    * No single-system lung involvement~ * Multi-system low-risk disease~    * Multiple organs involved but without involvement of risk organs~ * Single-system disease~    * Multifocal bone disease (i.e., lesions in 2 or more different bones)~   * Localized special site involvement, such as CNS-risk lesions with intracranial soft tissue extension or vertebral lesions with intraspinal soft tissue extension~      * Vault lesions are not regarded as CNS-risk lesions~PATIENT CHARACTERISTICS:~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception~PRIOR CONCURRENT THERAPY:~* No prior treatment for Langerhans cell histiocytosis

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).